Icotrokinra increases likelihood of Investigator's Global Assessment 0 or 1 by risk ratio 7.27Icotrokinra Shows Promise for Moderate to Severe Plaque Psoriasis

Clinical and experimental dermatology Published October 27, 2026 Study authors: Advani Sunaina, Raja Advait, Giraldo Tatiana, Aktaş Sümeyye, Lawal Ayomide, Gotor Alfonso PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that icotrokinra significantly improves IGA 0/1 and high-level skin clearance in plaque psoriasis patients.

This meta-analysis evaluates the efficacy of icotrokinra in adolescents and adults with moderate-to-severe plaque psoriasis. The analysis focuses on primary and secondary outcomes over a 16-week period to determine the treatment's impact compared to a placebo.

Key findings indicate that icotrokinra significantly improved clinical outcomes. Patients receiving icotrokinra showed an increased likelihood of achieving an Investigator's Global Assessment score of 0 or 1 at week 16, with a risk ratio of 7.27 (95% confidence interval 5.80-9.11). Additionally, high-level skin clearance (defined as a 90% improvement in Psoriasis Area and Severity Index) was significantly improved with a risk ratio of 13.8 (95% confidence interval 7.21-26.5).

The safety profile was reported as favorable, with adverse events and serious adverse events being comparable between icotrokinra and placebo. While the data suggests icotrokinra may offer biologic-level efficacy and ease of administration, the evidence is limited by the short-term 16-week follow-up period. Clinical utility should be weighed against the limited duration of the reported data.

How this fits prior evidence

This meta-analysis addresses a gap in the treatment landscape for moderate-to-severe plaque psoriasis by evaluating icotrokinra. It complements existing evidence regarding other high-performing treatments, such as guselkumab, secukinumab, and brodalumab, which are noted for high efficacy in PASI 90 and IGA 0/1. While previous coverage confirmed the efficacy of ustekinumab biosimilars and the comparable safety of BAT2306 to secukinumab, this finding adds a new agent with a risk ratio of 13.8 for high-level skin clearance to the available options.

Researchers analyzed data regarding icotrokinra, a new treatment for people with moderate to severe plaque psoriasis. The study included both adolescents aged 12 to 17 and adults over the age of 18. The goal was to see how well the treatment worked compared to a placebo over a 16-week period.

The results showed that patients taking icotrokinra had a much higher likelihood of achieving a low investigator score compared to those taking a placebo. Additionally, the treatment showed a significant improvement in high-level skin clearance, which is defined as at least a 90 percent improvement in the Psoriasis Area and Severity Index.

Safety data indicated that the treatment was well tolerated. The number of side effects and serious adverse events was similar between the group taking icotrokinra and the group taking the placebo. While these results are promising for psoriasis care, the data only covers a 16-week period. Talk to a doctor to see if this treatment fits your specific needs.

What this means for you:

Icotrokinra showed significant skin clearance and favorable safety for patients with moderate to severe plaque psoriasis.

Common questions

Who can benefit from icotrokinra?

Icotrokinra was studied in both adolescents aged 12 to 17 and adults aged 18 and older. These patients must have moderate to severe plaque psoriasis. The study showed it helped these specific groups achieve better skin clearance and improved assessment scores over 16 weeks.

Is icotrokinra safe for patients with psoriasis?

The study reported a favorable safety profile for icotrokinra. The number of side effects and serious adverse events was comparable between the group receiving icotrokinra and the group receiving a placebo. You should consult your doctor to discuss your specific health needs.

How effective is icotrokinra for skin clearance?

The study found that icotrokinra significantly improved high-level skin clearance. This is defined as at least a 90 percent improvement in the Psoriasis Area and Severity Index. It also showed a much higher likelihood of achieving a low investigator score compared to a placebo.

Study Details

Study typeMeta analysis

EvidenceLevel 1

Follow-up3.7 mo

PublishedOct 2026

PMID42308521

View Original Abstract ↓

BACKGROUND: In biologic therapies targeting interleukin (IL)-23 for plaque psoriasis, parenteral administration can limit treatment adherence and quality of life. Icotrokinra is a first-in-class oral peptide that selectively antagonizes the IL-23 receptor and has shown promising efficacy in phase II and phase III trials. However, a comprehensive synthesis of efficacy and safety across these trials is currently lacking. OBJECTIVES: To evaluate the efficacy and safety of icotrokinra in adolescents (12-17 years) and adults (≥ 18 years) with moderate-to-severe plaque psoriasis. METHODS: PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched on 8 December 2025, with reference lists hand-searched for additional studies. Randomized controlled trials enrolling the target population were included if they compared icotrokinra with placebo and reported efficacy or safety outcomes. RESULTS: Five randomized controlled trials (one phase II and four phase III), comprising four reports, met the inclusion criteria. Icotrokinra significantly increased the likelihood of achieving an Investigator's Global Assessment score of 0 or 1 at week 16 compared with placebo (risk ratio 7.27, 95% confidence interval 5.80-9.11), with no heterogeneity (I2 = 0%). High-level skin clearance, represented by ≥ 90% improvement in Psoriasis Area and Severity Index, was also significantly improved (risk ratio 13.8, 95% confidence interval 7.21-26.5). Rates of treatment-emergent and serious adverse events were comparable between icotrokinra and placebo, with no new safety signals identified over the 16-week trial period. CONCLUSIONS: Icotrokinra has shown short-term efficacy and a favourable safety profile in patients with moderate-to-severe plaque psoriasis. Combining biologic-level efficacy with ease of administration, icotrokinra may represent an important advance in psoriasis therapy.

Icotrokinra increases likelihood of Investigator's Global Assessment 0 or 1 by risk ratio 7.27Icotrokinra Shows Promise for Moderate to Severe Plaque Psoriasis

How this fits prior evidence

Common questions

Study Details

Adalimumab significantly improves ACR70 and PASI100 outcomes in patients with psoriatic arthritis

Trial data shows adalimumab helps manage psoriatic arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Icotrokinra increases likelihood of Investigator's Global Assessment 0 or 1 by risk ratio 7.27Icotrokinra Shows Promise for Moderate to Severe Plaque Psoriasis

How this fits prior evidence

Common questions

More on Plaque psoriasis

Study Details

Adalimumab significantly improves ACR70 and PASI100 outcomes in patients with psoriatic arthritis

Trial data shows adalimumab helps manage psoriatic arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Related in Dermatology

From Other Specialties